Publications

Pharmaceutics 2020 12 (6) 520
MANUSCRIPTS

      2019-2020

  1. Rosenblum D, Gutkin  A,  Kedmi K, Ramishetti  S,  Veiga N,  Jacobi A.M, Schubert M.S,  Friedmann- Morvinski D,  Cohen Z.R, Behlke M.A, Liberman J,  Peer D. (2020) CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. SCIENCE ADVANCES: EABC9450. PDF 

  2. Uebbing L, Ziller A, Siewert C,  Schroer M.A,  Blanchet C.E, Svergun D.I, Ramishetti S, Peer D, Sahin U,  Haas H and Langguth P. (2020 ) Investigation of pH-Responsiveness inside Lipid Nanoparticles for Parenteral mRNA Application Using Small-Angle X-ray Scattering. Langmuir. PDF
  3. Nogueira S, Schlegel A, Maxeiner K, Weber B, Barz M, Schroer M.A., Blanchet C.E, Svergun D, Ramishetti R, Peer D, Langguth P, Sahin U, and Haas H. (2020) Polysarcosine-Functionalized Lipid Nanoparticles for Therapeutic mRNA Delivery. ACS Applied NanoMaterials. PDF 

  4. Kon E, Hazan-Halevy I, Rosenblum D, Cohen N, Chatterjee S, Veiga N, Raanani P, Bairey O, Benjamini O, Nagler A, Peer D. (2020) Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics 12(6):E520. PDF

  5. Van de Vyver T, Bogaert B, De Backer L, Joris F, Guagliardo R, Van Hoeck J, Merckx P, Van Calenbergh S, Ramishetti S, Peer D, Remaut K, De Smedt SC, and Raemdonck K (2020) Cationic Amphiphilic Drugs Boost the Lysosomal Escape of Small Nucleic Acid Therapeutics in a Nanocarrier-Dependent Manner. ACS Nano. 14(4):4774-4791. PDF

  6. Ramishetti S, Hazan-Halevy I, Palakuri R, Chatterjee S, Naidu Gonna S, Dammes N, Freilich I, Kolik Shmuel L, Danino D, and Peer D (2020) A Combinatorial Library of Lipid Nanoparticles for RNA Delivery to Leukocytes. Adv Mater. 30:e1906128. PDF

  7. Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y, and Peer D (2020) An Ovarian Spheroid Based Tumor Model that Represents Vascularized Tumors and Enables the Investigation of Nanomedicine Therapeutics. Nanoscale 23;12(3):1894-1903. PDF

  8. Veiga N, Goldsmith M, Diesendruck Y, Ramishetti S, Rosenblum D, Elinav E, Behlke MA, Benhar I, and Peer D. (2019) Leukocyte-Specific siRNA Delivery Revealing IRF8 as a Potential Anti-Inflammatory Target. J Control Release.  313:33-41.  PDF

  9. Gao M, Deng J, Liu F, Fan A, Wang Y, Wu H, Ding D, Kong D, Wang Z, Peer D, and Zhao Y (2019) Triggered Ferroptotic Polymer Micelles for Reversing Multidrug Resistance to Chemotherapy. Biomaterials. 223:119486. PDF

  10. Hazan-Halevy I, Rosenblum D, Ramishetti S, and Peer D (2019) Systemic Modulation of Lymphocyte Subsets Using siRNAs Delivered via Targeted Lipid Nanoparticles. Methods Mol Biol. 1974:151-159. PDF

  11. Lusi V, Moore TL, Laurino F, Coclite A, Perreira R, Ferreira M1, Rizzuti I, Palomba R, Zunino P, Duocastella M4, Mizrahy S, Peer D, Decuzzi P (2019) A Tissue Chamber Chip for Assessing Nanoparticle Mobility in the Extravascular Space. Biomed Microdevices. 21(2):41. PDF

  12. Edri R, Gal I, Noor N, Harel T, Fleischer S, Adadi N, Green O, Shabat D, Heller L, Shapira A, Gat-Viks I, Peer D, and Dvir T (2019) Personalized Hydrogels for Engineering Diverse Fully Autologous Tissue Implants. Adv Mater. 31(1):e1803895. PDF 

      2017-2018

  1. Liu G, Deng J, Liu F,  Wang Z, Peer  D and  Zhao Y (2018) Hierarchical Theranostic Nanomedicine: MRI Contrast Agents as a Physical Vehicle Anchor for High Drug Loading and Triggered on-demand Delivery. J. Mat. Chem. B 6:1995–2003.  PDF

  2. Veiga N, Goldsmith M, Granot Y, Rosenblum D, Dammes N, Kedmi R, Ramishetti S, and Peer D (2018) Cell-Specific Delivery of Modified mRNA Expressing Therapeutic Proteins to Leukocytes. Nat Commun. 9(1):4493-449. PDF

  3. Goldsmith M,  Abramovitz L, Braunstein H, Horowitz M, and Peer D (2018) Quantitative Analysis of Recombinant Glucocerebrosidase Brain Delivery via Lipid Nanoparticles. Nano Futures 2(4). PDF

  4. Kedmi R*, Veiga N*, Ramishetti S, Goldsmith M, Rosenblum D, Dammes N, Hazan-Halevy I,  Nahary L,  Leviatan-Ben-Arye S, Harlev M, Behlke M, Benhar I, Lieberman J, and Peer D (2018) A Modular Platform for Targeted RNAi Therapeutics. Nature Nanotechnology 13(3):214-219.  *denotes equal contribution PDF

  5. Karp J. M. and Peer D. (2018) Editorial: Focus on RNA interference: from nanoformulations to in vivo delivery. Nanotechnology 29(1):010201. PDF

  6. Zyuzin MV, Díez P, Goldsmith M, Carregal-Romero S, Teodosio C, Rejman J, FeliuN, Escudero A, Almendral MJ, Linne U, Peer D, Fuentes M, and Parak WJ (2017). Comprehensive and Systematic Analysis of the Immunocompatibility of Polyelectrolyte Capsules. Bioconjug Chem. PDF

      2015-2016

  1. Soffer-Tsur N., Peer D., and Dvir T (2016)  ECM-based Macroporous Sponges Release Essential Factors to Support the Growth of Hematopoietic Cells. Journal of Controlled Release 257:84-90. PDF

  2. Kedmi R, and Peer D. (2016) Zooming in on Selectins in Cancer. Sci. Transl. Med.  8(345):1-2. PDF

  3. Weinstein S,  Toker, IA, Emmanuel R, Ramishetti R, Hazan-Halevy I, Rosenblum D, Goldsmith M, Abrahamc A, Benjamini B, Bairey O, Raanani R, Nagler A, Liebermane J and Peer D (2016) Harnessing RNAi Based-Nanomedicines for Therapeutic Gene Silencing in B cell Malignancies.  Proc. Natl. Acad. Sci. USA 113(1) E16-E22. PDF

  4. Dearling, J, Daka, A, Veiga, N, Peer, D, and Packard A (2016) ImmunoPET of Colitis: Defining Target Cell Populations and Optimizing Pharmacokinetics. Inflammatory Bowel Diseases 22(3):529-538. PDF

  5. Ben-Arye T., Park S., Shemesh J., Peer D., Levenberg S. and Yossifon G (2015) Dielectrophoretic Characterization of Cells in a Stationary Nanoliter Droplet Array with Generated Chemical gradients. Biomed Microdevices 17: 91PDF

  6. Ramishetti S*, Kedmi R*, Goldsmith M, Leonard F, Speague AG, Godin B, Gozin M, Cullis P, Dykxhoorn DM, and Peer D (2015) Systemic Gene Silencing in Primary T lymphocytes using Targeted Lipid Nanoparticles. ACS Nano 9(7):6706-6716 *denotes equal contribution. PDF

  7. Yang D, Zeng T, Yang Y, Wang X, Hu J, Song Y, Chen L, Peer D, Wang X, and Bai C (2015) Specific Serum Chemokines Network Correlates Chemotherapy in Non-small-cell Lung Cancer. Cancer Letters. 365(1), 57-67. PDF

  8. Hazan-Halevy I*, Rosenblum D*,Weinstein S, Bairey O, Raanani P,  and Peer D (2015) Cell-specific Uptake of Mantle Cell Lymphoma-Derived Exosomes by Malignant and Non-Malignant B-Lymphocytes. Cancer Letters. 364(1), 59-69. *denotes equal contribution. PDF

  9. Sigal N, Kaplan Zeevi M, Weinstein S, Peer D and Herskovits AA (2015). The Human P-glycoprotein Transporter enhances Type I Interferon Response to L. monocytogenes Infection. Infection and Immunity. 83(6), 2358-2368. PDF

  10. Jacoby G*, Cohen K*, Tamon I, and Peer D*. and Back-Barkai R* (2015) Metastability in lipid-Based Particles Exhibits Temporally Deterministic and Controllable Behavior. Scientific Reports 5, 9481, 1-7.*denotes equal contribution. PDF

  11. Cao Y, Gao M, Chen C., Fan A. Zhang J, Kong D, Wang Z, Peer, D and Zhao, Y (2015) Triggered-Release Polymeric Conjugate Micelles for on-Demand Intracellular Drug Delivery. Nanotechnology 26, 1-9. PDF

  12. Cohen ZR*, Ramishetti S*, Peshes-Yaloz N*, Goldsmith M, Wohl A, Zibly Z, and Peer D (2015). Localized RNAi Therapeutics of Chemo-Resistant Grade IV Glioma using Hyaluronan-Grafted Lipid-Based Nanoparticles. ACS Nano. 9(2), 1581-1591.*denotes equal contribution,  PDF

  13. Perevedentseva E, Peer D, Uvarov V, Zousman B, and Levinson O (2015) Nanodiamonds of Laser Synthesis for Biomedical Applications. J. Nanosci. Nanotech. 15(2), 1045-1052.PDF

      2013-2014

  1. Drinberg V, Bitcover R, Rajchenbach W, and Peer D (2014) Modulating Cancer Multidrug Resistance by Sertraline in Combination with a Nanomedicine. Cancer Letters 354, 290-298. PDF

  2. Soffer-Tsur N, Shevach M, Shapira A, Peer D, and Dvir T (2014) Optimizing the Biofabrication Process of Momentum-Based Scaffolds for Engineering Autologous Tissues. Biofabrication 6. PDF

  3. Amar-Lewis E, Azagury A, Goldbart R, Traitel T, Prestwood J, Landesman-Milo D, Peer D, and Kost J. (2014) Quaternized Starch-based Carrier for siRNA Delivery: from Cellular Uptake to Gene Silencing. Journal of Controlled Release 185, 118-120. PDF

  4. Cohen K, Emmanuel R, Kisin-Finfer E, Shabat D, and Peer, D. (2014) Modulation of Drug Resistance in Ovarian Adenocarcinoma using Chemotherapy Entrapped in Hyaluronan-Grafted Nanoparticle Clusters. ACS Nano 8(3), 2185-2193. PDF

  5. Mizrahy S, Goldsmith M, Leviatan-Ben-Arye S, Kisin-Finfer E, Redy O, Srinivasan S, Shabat D, Godin B, and Peer D. (2014) Tumor Targeting Profiling of Hyaluronan-Coated Lipid Based-Nanoparticles. Nanoscale 6, 3742-3752. PDF

  6. Amram S, Ganoth A, Tichon O, Peer D, Nachliel E, Gutman M, and Tsfadia Y (2014) Structural Characterization of the Drug Translocation Path of MRP1/ABCC1. Israeli Journal of Chemistry 54, 1382-1393. PDF

  7. Peer D, and Howard KA (2014). RNA Interference-based Therapeutics and Diagnostics. Drug Delivery and Translation Research 4, 1-2. PDF

  8. Landesman-Milo D, and Peer D (2014) Toxicity Profiling of Several Common RNAi-based Nanomedicines: A Comparative Study. Drug Delivery and Translational Research  (1):96-103. PDF

  9. Wang X., Peer D., and Petersen B (2013) Molecular and Cellular Therapies: New Challenges and Opportunities. Molecular and Cellular Therapies 1, 1-4.  PDF

  10. Dahan L, Huang L, Kedmi R, Behlke MA, and Peer D (2013) SNP Detection in mRNA in Living Cells Using Allele-Specific FRET Probes. PLoS ONE 8(9) e72389. PDF

  11. Dvash R, Khatchatouriants A, Solmesky LJ, Wibroe PP, Weil M, Moghimi SM, and Peer D (2013) Structural Profiling and Biological Performance of Phospholipid-Hyaluronan Functionalized Single-Walled Carbon Nanotubes. Journal of Controlled Released 170, 295-305. PDF

  12. Emmanuel R, Weinstein S, Landesman-Milo D, and Peer D (2013) eiF3c: A Potential Therapeutic Target for Cancer. Cancer Letters 336, 158-166. PDF

  13. Elinav E, and Peer D. (2013) Harnessing Nanomedicine for Mucosal Theranostics-A Silver Bullet at Last? ACS Nano. 7(4), 2883-2890. PDF

  14. Landesman-Milo D, Goldsmith M, Arie SL, Witenberg B, Brown E,  Leibovitch S, Azriel S, Tabak S, Morad V, and Peer D (2013) Hyaluronan Grafted Lipid-Based Nanoparticles as RNAi Carriers for Cancer Cells. Cancer Letters 334, 221-227. PDF

      2010-2012

  1. Weinstein S, Emmanuel R, Jacobi AM, Abraham A, Behlke MA, Sprague AG, Novobrantseva TI, Nagler A, and Peer D (2012) RNA Inhibition Highlights Cyclin D1 as a Potential Therapeutic Target for Mantle Cell Lymphoma. PLoS One 7(8):e43343. PDF

  2. Moyano D, Goldsmith M, Solfiell D, Landesman-Milo D, Miranda O, Peer D,* and Rotello VM* (2012). Hydrophobicity Dictates Immune Response. Journal of American Chemical Society 134(9), 3965-3967. *denotes equal contribution. PDF

  3. Ben-Arie N, Kedmi R, and Peer D (2012). Integrin-Targeted Nanoparticles for siRNA Delivery. Methods in Molecular.757, 497-507. PDF

  4. Srinivasan C, Peer D, and Shimaoka M (2012). Integrin Targeted Stabilized Nanoparticles for an efficient Delivery of siRNAs in vitro and in vivo. Methods in Molecular Biology 820, 105-116. PDF

  5. Breiner-Goldstein E, Evron Z, Frenkel M, Cohen K, Nir Meiron K, Peer D, Roichman Y, Flescher E, and Fridman M (2011) Targeting Anthracycline-resistant Tumor Cells with Synthetic Aloe-emodin Glycosides. ACS Medicinal Chemistry Letters2, 528-531. PDF

  6. Solmesky LJ, Shuman M, Goldsmith M, Weil M, and Peer D (2011) Assessing Cellular Toxicities in Fibroblasts upon Exposure to Lipid-Based Nanoparticles: a High Content Analysis Approach. Nanotechnology 22(49), 494016. PDF

  7. Moghimi SM, Peer D, and Langer R (2011) Reshaping the Future of Nanopharmaceuticals: Ad ludicium. ACS Nano. 5(11), 8454-8458. PDF

  8. Mizrahy S, Raz SR, Hasgaard M, Liu H, Soffer-Tsur N, Cohen K, Dvash R, Landsman-Milo D, Bremer MG, Moghimi SM, and Peer D (2011) Hyaluronan-Coated Nanoparticles: The Influence of the Molecular Weight on CD44-Hyaluronan Interactions and on the Immune Response. Journal of Controlled Release 156(2), 231-238. PDF

  9. Bachar G, Cohen K, Hod R, Feinmesser R, Mizrachi A, Shpitzer T, Katz O, and Peer D (2011) Hyaluronan-Grafted Particle Clusters loaded with Mitomycin C as Selective Nanovectors for Primary Head and Neck Cancers. Biomaterials 32(21), 4840-4848. PDF

  10. Kim SS, Subramanya S, Peer D, Shimaoka M, and Shankar P (2011) Antibody-Mediated Delivery of siRNAs for anti-HIV Therapy. Methods Mol. Biol. 721,339-353. PDF

  11. Drug E, Landesman-Milo D, Belgorodsky B, Ermakov N, Frenkel-Pinter M, Fadeev L, Peer D, and Gozin M (2011) Enhanced Bioavailability of Polyaromatic Hydrocarbons in the Form of Mucin Complexes. Chemical research in toxicology 24(3), 314-320. PDF

  12. Cohen-Kupiec R, Weinstein S, Kantor G, Peer D, and Weil M (2010) IKAP/hELP1 Down-Regulation in Neuroblastoma Cells Causes Enhanced Cell Adhesion Mediated by Contactin Overexpression. Cell Adh. Migr. 4(4):541-550. PDF

  13. Rivkin I, Cohen K, Koffler J, Melichov D., Peer D*, and Margalit R* (2010) Paclitaxel-Clusters Coated with Hyaluronan as Selective Tumor-Targeted Nanovectors. Biomaterials 31, 7106-7114. *denotes equal contributionPDF

  14. Kedmi R*, Ben-Arie N*, and Peer D (2010). The Systemic Toxicity of Positively Charged Lipid Nanoparticles and the Role of Toll-like receptor 4 in Immune Activation. Biomaterials 31, 6867-6875. *denotes equal contribution. PDF

  15. Dearling JLJ, Voss S, Dunning P, Park EJ, Fahey F, Treves T Solapino S., Shimaoka M, Packard AB, and Peer D (2010) Detection of Intestinal Inflammation by microPET Imaging Using a 64Cu-Labeled Anti-b7 Integrin Antibody. Inflammatory bowel diseases16(9), 1458-1466. PDF

  16. Kim S-S*, Peer D*, Kumar P*, Subramanya S, Wu H, Asthana D, Habiro K, Yang Y-G, N. Manjunath, Shimaoka M and Shankar P (2010) RNAi-mediated CCR5 silencing by LFA-1-targeted Nanoparticles Prevents HIV Infection in BLT mice. Molecular Therapy 18, 370-376. * denotes equal contribution. PDF

      2000-2009

  1. Argov M, Kashi R, Peer D, and Margalit R (2009) Treatment of Resistant Human Colon Cancer Xenografts by a Fluoxetine-Doxorubicin Combination Enhances Therapeutic Responses Comparable to an Aggressive Bevacizumab Regimen. Cancer Letters 274(1), 118-125. PDF

  2. Imai Y, Park EJ, Peer D, Peixoto A, Cheng G, von Andrian UH, Carman CV, and Shimaoka M (2008) Genetic Perturbation of the Putative Cytoplasmic Membrane-Proximal Salt Bridge Aberrantly Activates alpha(4) Integrins. Blood 112(13), 5007-5015. PDF

  3. Peer D, Park EJ, Morishita Y, Carman CV, and Shimaoka M (2008) Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammation Target. Science 319, 627-630. PDF

  4. Peer D, Zhu P, Carman CV, Lieberman J, and Shimaoka M (2007) Selective Gene Silencing in Activated Leukocytes by Targeting siRNAs to the Integrin Lymphocyte Function-Associated Antigen-1. Proc. Natl. Acad. Sci. USA, 104, 4095-4100. PDF

  5. Shimaoka M, Kim M, Cohen EH, Yang W, Astrof N, Peer D, Salas A, Ferrand A, and Springer TA. (2006) AL-57, a Ligand-Mimetic Antibody to Integrin LFA-1, Reveals Chemokine-Induced Affinity Up-Regulation in Lymphocytes. Proc. Natl. Acad. Sci. USA 103(38):13991-13996. PDF

  6. Peer D, Dekel Y, Melikhov D, and Margalit R (2004) Fluoxetine Inhibits MDR Extrusion Pumps and Enhances Therapeutic responses to Chemotherapy in Syngeneic and Human Xenograft Mouse Tumor Models. Cancer Research 64, 7562-7569. PDF

  7. Peer D, and Margalit R (2004) Tumor-Targeted Hyaluronan Nanoliposomes Increase the Antitumor Activity of Liposomal Doxorubicin in a Syngeneic and Human Xenografts Mouse Tumor. Neoplasia 6, 343-353. PDF

  8. Peer D, and Margalit R (2004)  Loading Mitomycin C Inside Long-Circulating Hyaluronan Targeted Nano-Liposomes Increases its Antitumor Activity in Three Mice Tumor Models. Int. Journal of Cancer 108(5):780-789. PDF

  9. Peer D, Florentin A, and Margalit R. (2003) Hyaluronan is a Key Component in Cryoprotection and Formulation of Targeted Unilamellar Liposomes. Biochim Biophys. Acta. 1612(1), 76-82. PDF

  10. Peer D, and Margalit R (2000) Physicochemical Evaluation of a Stability-Driven Approach to Drug Entrapment in Regular and in Surface-Modified Liposomes. Arch. Biochem. Biophys. 383,185–190. PDF

REVIEWS

    2019-2020

  1. Dammes N, Peer D (2020) Paving the road for RNA therapeutics. Trends in Pharmacological Sciences 41(10):755-775. PDF

  2. Rosenblum D, Gutkin A, Dammes N,  Peer D (2020) Progress and challenges towards CRISPR/Cas clinical translation. Adv Drug Deliv Rev. S0169(20): 30080-30086. PDF

  3. Veiga N,  Diesendruck Y, and Peer D (2020) Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev. S0169(20): 30022-30033. PDF

  4. Dammes N, and Peer D (2020) Monoclonal Antibody-Based Molecular Imaging Strategies and Theranostic Opportunities. Theranostics. 10(2):938-955. PDF

  5. Moghimi SM, and Peer D (2019) Reprogramming the Lymphocyte Axis for Immunotherapy. Advanced Drug Delivery Reviews 141  1–2. PDF

  6. Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, and Michelassi F (2019) Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis. 25:S24-S30. PDF

  7. Granot-Matok Y,  Kon E, Dammes N, Mechtinger G, and Peer D (2019) Therapeutic mRNA Delivery to Leukocytes. Journal of Controlled Release 305, 165-175. PDF

  8. Dhyani M, Joshi N, Bemelman WA,  Gee MS, Yajnik V,  D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G,  Lu TK,  Lineberry N,  Niessen HG, Peer D,  Braun J,   Delaney CP,  Dubinsky MC, Guillory AN,  Pereira M, Shtraizent N, Honig G,  Polk DB, Hurtado-Lorenzo A,  Karp JM,  and Michelassi  F (2019) Challenges in IBD Research: Novel Technologies. Inflamm. Bowel Dis.  25,(2), S24-S30. PDF

  9. Mizrahy S, Gutkin A, Decuzzi P, and Peer D (2019) Targeting central nervous system pathologies with nanomedicines. J. Drug Target. 27(5-6):542-554. PDFT

    2019-2020

  1. Dammes N, Peer D (2020) Paving the road for RNA therapeutics. Trends in Pharmacological Sciences 41(10):755-775. PDF

  2. Rosenblum D, Gutkin A, Dammes N,  Peer D (2020) Progress and challenges towards CRISPR/Cas clinical translation. Adv Drug Deliv Rev. S0169: 30080-30086. PDF

  3. Veiga N,  Diesendruck Y, and Peer D (2020) Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev. 2020 PDF

  4. Dammes N, and Peer D (2020) Monoclonal Antibody-Based Molecular Imaging Strategies and Theranostic Opportunities. Theranostics. 10(2):938-955. PDF

  5. Moghimi SM, and Peer D (2019) Reprogramming the Lymphocyte Axis for Immunotherapy. Advanced Drug Delivery Reviews 141  1–2. PDF

  6. Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, and Michelassi F (2019) Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis. 25:S24-S30. PDF

  7. Granot-Matok Y,  Kon E, Dammes N, Mechtinger G, and Peer D (2019) Therapeutic mRNA Delivery to Leukocytes. Journal of Controlled Release 305, 165-175. PDF

  8. Dhyani M, Joshi N, Bemelman WA,  Gee MS, Yajnik V,  D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G,  Lu TK,  Lineberry N,  Niessen HG, Peer D,  Braun J,   Delaney CP,  Dubinsky MC, Guillory AN,  Pereira M, Shtraizent N, Honig G,  Polk DB, Hurtado-Lorenzo A,  Karp JM,  and Michelassi  F (2019) Challenges in IBD Research: Novel Technologies. Inflamm. Bowel Dis.  25,(2), S24-S30. PDF

  9. Mizrahy S, Gutkin A, Decuzzi P, and Peer D (2019) Targeting central nervous system pathologies with nanomedicines. J. Drug Target. 27(5-6):542-554. PDF

    2019-2020

  1. Dammes N, Peer D (2020) Paving the road for RNA therapeutics. Trends in Pharmacological Sciences 41(10):755-775. PDF

  2. Rosenblum D, Gutkin A, Dammes N,  Peer D (2020) Progress and challenges towards CRISPR/Cas clinical translation. Adv Drug Deliv Rev. S0169: 30080-30086. PDF

  3. Veiga N,  Diesendruck Y, and Peer D (2020) Targeted lipid nanoparticles for RNA therapeutics and immunomodulation in leukocytes. Adv Drug Deliv Rev. 2020 PDF

  4. Dammes N, and Peer D (2020) Monoclonal Antibody-Based Molecular Imaging Strategies and Theranostic Opportunities. Theranostics. 10(2):938-955. PDF

  5. Moghimi SM, and Peer D (2019) Reprogramming the Lymphocyte Axis for Immunotherapy. Advanced Drug Delivery Reviews 141  1–2. PDF

  6. Dhyani M, Joshi N, Bemelman WA, Gee MS, Yajnik V, D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G, Lu TK, Lineberry N, Niessen HG, Peer D, Braun J, Delaney CP, Dubinsky MC, Guillory AN, Pereira M, Shtraizent N, Honig G, Polk DB, Hurtado-Lorenzo A, Karp JM, and Michelassi F (2019) Challenges in IBD Research: Novel Technologies. Inflamm Bowel Dis. 25:S24-S30. PDF

  7. Granot-Matok Y,  Kon E, Dammes N, Mechtinger G, and Peer D (2019) Therapeutic mRNA Delivery to Leukocytes. Journal of Controlled Release 305, 165-175. PDF

  8. Dhyani M, Joshi N, Bemelman WA,  Gee MS, Yajnik V,  D’Hoore A, Traverso G, Donowitz M, Mostoslavsky G,  Lu TK,  Lineberry N,  Niessen HG, Peer D,  Braun J,   Delaney CP,  Dubinsky MC, Guillory AN,  Pereira M, Shtraizent N, Honig G,  Polk DB, Hurtado-Lorenzo A,  Karp JM,  and Michelassi  F (2019) Challenges in IBD Research: Novel Technologies. Inflamm. Bowel Dis.  25,(2), S24-S30. PDF

  9. Mizrahy S, Gutkin A, Decuzzi P, and Peer D (2019) Targeting central nervous system pathologies with nanomedicines. J. Drug Target. 27(5-6):542-554. PDFT

     2017-2018

  1. Ramishetti S, and Peer D (2018) Engineering lymphocytes with RNAi. Adv Drug Deliv Rev. 141:55-66.  PDF

  2. Gutkin A, and Peer D (2018) Gene Silencing in the Right Place at the Right Time. Mol Ther. 5;26(12):2875.  PDF

  3. Rosenblum D, Joshi N, Tao W, Karp J.M,  and Peer D (2018) Progress and Challenges Towards Targeted Delivery of Cancer Therapeutics. Nature Communications 9, 1-12. PDF

  4. Granot Y,  and Peer D (2017) Delivering the Right Message: Challenges and Opportunities in Lipid Nanoparticles-Mediated Modified mRNA Therapeutics- An Innate Immune System Standpoint. Semin Immunol 34:68-77. PDF

  5. Rietwyk S, and Peer D (2017) Next-Generation Lipids in RNA Interference Therapeutics. ACS Nano 11, 7572−7586. PDF

  6. Alvarez MM, Aizenberg J, Analoui M, Andrews AM, Bisker G, Boyden ES, Kamm R.D, Karp JM, Mooney DJ, Oklu R, Peer D, Stolzoff M,  Strano MS, Trujillo-de Santiago G, Webster TJ, Weiss PS, and Khademhosseini A (2017) Emerging Trends in Micro- and Nanoscale Technologies in Medicine: from Basic Discoveries to Translation. ACS Nano 11, 5195-5214. PDF

  7. Mizrahy S, Hazan-Halevy I, Dammes N, Landesman-Milo D, and Peer D (2017) Current Progress in Non-viral RNAi-Based Delivery Strategies to Lymphocytes. Molecular Therapy 25, 1491-1500. PDF

  8. Mizrahy S, Hazan-Halevy I, Landesman-Milo D,  and  Peer D (2017) Advanced strategies in Immune Modulation of Cancer using Lipid-Based Nanoparticles. Frontiers in Immunology 8, 69. PDF

  9. Anchordoquy TJ,  Barenholz Y,  Boraschi D, Chorny M,  Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS,  Farrell D, Gabizon A, Ghandehari H, Godin B, La-Beck NM, Ljubimova J, Moghimi SM, Pagliaro L,  Park JH,  Peer D, Ruoslahti E, Serkova NJ, and Simber D (2017) Mechanisms and Barriers in Cancer Nanomedicine: Addressing Challenges, Looking for Solutions. ASC Nano.  PDF

  10. Ng BD, and Peer D (2017) Orchestrating a Symphony on a Single Conjugate: Aptamer Targeting, Gene Silencing, and Immunomodulation to Enhance Antitumor Response. Molecular Therapy 25, 5-7. PDF

     2015-2016

  1. Hazan-Halevy I, Landesman-Milo D, Rosenblum D, Mizrahy S, Ng BD, and Peer D (2016) Immunomodulation of Hematological Malignancies using Oligonucleotides Based-Nanomedicines. Journal of Controlled Release, 244, 149-156. PDF

  2. Gutkin A, Cohen ZR, and Peer D (2016) Harnessing Nanomedicine for Therapeutic Intervention in Glioblastoma. Expert Opinion on Drug Delivery ISSN: 1744-7593, 1573-1582. PDF

  3. Ramishetti S, Landesman-Milo D, and Peer D (2016) Advances in RNAi Therapeutic Delivery to Leukocytes Using Lipid Nanoparticles. J Drug Target. 24(9):780-786. PDF

  4. Singh MS, and Peer D (2016) siRNA Delivery: Current Trends and Future Perspectives.  Ther Deliv. 51-53. PDF

  5. Singh MS, Peer D (2016) RNA Nanomedicines: the Next Generation of Drugs? Current Opinion in Biotechnology 28-34. PDF

  6. Landesman-Milo D, and Peer D (2016) Transforming Nanomedicines from Lab-Scale Production to Novel Clinical Modality. Bioconjug Chem. 27(4):855-862. PDF

  7. Moyano DF, Liu Y., Peer D and Rotello VM (2016) Modulation of immune response using engineered nanoparticle surfaces. Small 12(1),76-82. PDF

  8. Moghimi SM, Hunter AC, and Peer D (2016) Platelet Mimicry: The emperor’s New Clothes? Nanomedicine 12, 245-248. PDF

  9. Landesman-Milo D, Ramishetti S, and Peer D (2015) Nanomedicine as an Emerging Platform for Metastatic Lung Cancer Therapy. Cancer and Metastasis Reviews 34(2), 291-301. PDF

  10. Ganoth A, Cohen K.M, and Peer D (2015) Overcoming Multidrug Resistance with Drug Delivery Strategies. Expert Opin Drug Deliv.  12(2):223-238. PDF

     2013-2014

  1. Peer D (2014) Precision medicine – delivering the goods? Cancer Letters 352, 2-3PDF

  2. Goldsmith M, Abramovitz L, and Peer D (2014) Precision Nanomedicine in Neurodegenerative Diseases. ACS Nano 8(3), 1958-1965. PDF

  3. Bogart K., Pourroy G, Murphy CJ, Puntes VF, Pellegrino T, Rosenblum D, Peer D*, and Lévy R* (2014) Nanoparticles for Imaging, Sensing, and Therapeutic Intervention. ACS Nano 8(4), 3107–3122. *denotes equal contribution. PDF

  4. Peer D (2014) Harnessing RNAi Nanomedicine for Precision Therapy. Molecular and Cellular Therapies 2(5), 2-11.PDF

  5. Rosenblum D, and Peer D (2014) Omics-Based Nanomedicine: The Future of Personalized Oncology. Cancer Letters. 352, 126-136. PDF

  6. Peer D, Giannechi N. and Luo D (2013) Nanoparticles in Biology. Journal of Materials Chemistry . PDF

  7. Mizrahy S, Landesman-Milo D, and Peer D (2013) Sweet Fairytale: Carbohydrates as Backbones for Glyconanomedicine. Israel Journal of Chemistry 53 (9-10), 616-629. PDF

  8. Howard KA. and Peer D (2013) Providing the Full Picture: a Mandate for Standardizing Nanoparticle-Based Drug Delivery.Nanomedicine (Lond). 8(7):1031-1033. PDF

  9. Peer D (2013) A Daunting Task: Manipulating Leukocyte Function with RNAi. Immunol Rev. 253, 185197. PDF

     2006-2012

  1. Vorup-Jensen T, and Peer D (2012) Nanotoxicity and the Importance of Being Earnest. Adv. Drug Deliv. Rev. 64 (15) 1661-1662.PDF

  2. Daka A, and Peer D (2012) RNAi-Based Nanomedicines for Targeted Personalized Therapy. Adv. Drug Deliv. Rev. 64(13), 1508-1521. PDF

  3. Peer D (2012) Immunotoxicity Derived from Manipulating Leukocytes with Lipid-based Nanoparticles. Adv. Drug Deliv. Rev. 64 (15), 1738–1748. PDF

  4. Barenholz Y, and Peer D (2012) Liposomes, lipid Biophysics, and Sphingolipid Research: from Basic to Translational Research. Chemistry & Physics of Lipids 165, 363-364. PDF

  5. Barenholz Y, and Peer D (2012) Liposomes and other Assemblies as Drugs and Nano-Drugs: from basic and Translational Research to the Clinics. Journal of Controlled Release 160(2), 115-116. PDF

  6. Landsman–Milo D, and Peer D (2012) Altering the Immune Response with liposomes. Journal of Controlled Release 161, 600-608. PDF

  7. Mizrahy S, and Peer D (2012). Polysaccharides as Building Blocks for Nanotherapeutics. Chem. Soc. Rev. 41, 2623–2640. PDF

  8. Goldsmith M, Mizrahy S, and Peer D (2011) Grand Challenges in Modulating the Immune Response with RNAi Nanomedicines. Nanomedicine 6(10), 1771-1785. PDF

  9. Peer D, and Lieberman J (2011) Special Delivery: Targeted Therapy with Small RNAs. Gene therapy 18(12), 1127-1133. PDF

  10. Elfakess R, and Peer D (2010) Overcoming RNAi Transduction in Leukocytes using Targeted and Stabilized Nanoparticles. IDrugs 13(9), 626-631. PDF

  11. Weinstein S, and Peer D (2010) RNAi Nanomedicines: Challenges and within Opportunities the Immune System. Nanotechnology 21(23), 232001, 1-13. PDF

  12. Peer D (2010) Induction of Therapeutic Gene Silencing in Leukocyte-Implicated Diseases by Targeted and Stabilized Nanoparticles: a mini-review. Journal of Controlled Release. 148(1), 63-68. PDF

  13. Kedmi R, and Peer D (2009) RNAi Nanoparticles in the Service of Personalized Medicine. Nanomedicine 4(8), 853-855PDF

  14. Peer D, and Shimaoka M (2009) Systemic siRNA Delivery to Leukocyte-Implicated Diseases. Cell Cycle 8, 853-859. PDF

  15. Peer D, Karp JM, Hong S, Farokhzad O, Margalit R, and Langer R (2007) Nanocarriers as an Emerging Platform for Cancer Therapy. Nature Nanotechnology 2, 751-760. PDF

  16. Klausner EA, Peer D, Chapman RL, Multack RF, and Andurkar SV. (2007) Corneal Gene Therapy. Journal of Controlled Release 124(3), 107-133. PDF

  17. Peer D, and Margalit R (2006) Fluoxetine and Reversal of Multidrug Resistance. Cancer Letters 237,180-187. PDF

BOOKS
  1. Howard KA, Jensen T, Peer D  (2016) Nanomedicine. Springer Publishing.

  2. Peer D  (2013) Nanotechnology for Delivery of Therapeutic Nucleic Acids. Pan Stanford Publishing.

  3. Peer D (2012) Handbook of Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications. Pan Stanford Publishing.

COMMENTARIES
  1. MacLachlan I (2008) siRNAs with Guts. Nature Biotechnology 26, 403 – 405. PDF

  2. Mullard A (2008) Escorting siRNA. Nature Reviews Molecular Cell Biology 9, 189. PDF

  3. Szoka F (2008) The Art of Assembly. Science 319 (5863), 578-579. PDF

  4. Weintraub K (2013)  The New Gold Standard. Nature 495, S14-S16PDF

  5. Sarmento B, Das Neves J,  Santos HA,  Santos L, MitragotriS, Little S,  Peer D, Amiji  MM, and Alonso MJ (2019) On the issue of transparency and reproducibility in nanomedicine. Nature Nanotechnology 14, 629–635. PDF